Fluvastatin inhibits up‐regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells
- 26 August 2004
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (9) , 1558-1563
- https://doi.org/10.1111/j.1538-7836.2004.00896.x
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- The role of tissue factor in the antiphospholipid syndromeArthritis & Rheumatism, 2001
- Experimental Thrombosis and Antiphospholipid Antibodies: New InsightsJournal of Autoimmunity, 2000
- Antiphospholipid Antibodies and the Protein C PathwayJournal of Autoimmunity, 2000
- Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cellsLife Sciences, 2000
- State-of-the-Art-Review : Statins Induce Hypothrombotic States?Clinical and Applied Thrombosis/hemostasis, 2000
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- FluvastatinDrugs, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell lineInternational Journal of Immunopharmacology, 1996
- SYNDROME OF THE BLACK SWANRheumatology, 1987